Recombinant Proteins Market Size by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
Report Code: BT 7839 Jan, 2024, by marketsandmarkets.com
The size of global recombinant proteins market in terms of revenue was estimated to be worth $2.2 billion in 2023 and is poised to reach $3.2 billion by 2028, growing at a CAGR of 7.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
Growth in the market can be attributed to factors such as rising incidence of chronic diseases, growing demand for biologics and biosimilars due to expiration of patents, rising demand for customized medicine and increasing government initiatives for R&D in life sciences research.
Attractive Opportunities in the Recombinant proteins Market
To know about the assumptions considered for the study, Request for Free Sample Report
Global Recombinant Proteins Market Dynamics
Driver: Rising incidence of chronic diseases
The rising prevalence of chronic diseases has ultimately driven the demand for precise & effective protein therapeutic interventions.. The American Cancer Society estimates the number of new cancer cases and deaths each year, with common types including lung, breast, colorectal, prostate, and skin cancers. Various factors contribute to cancer risk, including tobacco use, poor diet, lack of physical activity, excessive sun exposure, and exposure to certain chemicals and pollutants. Breast, lung and bronchus, prostate, and colorectal cancers account for almost 50% of all new cancer cases in the United States. Lung and bronchus, colorectal, pancreatic, and breast cancers are responsible for nearly 50% of all deaths. For instance, in 2022, there were ~1.9 million new cancer cases diagnosed; of which 609,360 individuals died in the US as per the American Cancer Society. Cancer is the second most common cause of death in the US. In 2022, an estimated 89,010 new cases of lymphoma were diagnosed in the US.
Restraint: High production costs
Advancements in recombinant DNA technologies have opened avenues for the production of therapeutic, vaccine, and diagnostic recombinant proteins. These proteins are predominantly manufactured using prokaryotic & eukaryotic expression host systems, including mammalian cells, bacteria, yeast, insect cells, and transgenic plants, both in laboratory and large-scale settings. However, the high production costs associated with recombinant proteins stem from a multitude of factors across the production pipeline. Upstream processes, comprising cell culture & fermentation, requires considerable resources for large-scale production, including costly media, equipment, and facility maintenance. The development of efficient bioprocessing strategies is crucial for industrial production of recombinant proteins of therapeutic and prophylactic importance. Several initiatives are being opted to reduce the overall production cost burden. For instance, in February 2023, Future Fields (Canada) raised USD 11.2 million to expand its fruit fly biomanufacturing platform for the production of recombinant proteins
Opportunity: Advancements in gene editing technologies
Gene editing technologies are increasingly playing a crucial role in the development & optimization of recombinant proteins. These technologies empower researchers to make precise modifications to the genetic code, providing a method to enhance the expression, stability, and functionality of proteins produced using recombinant DNA technology. CRISPR-Cas9, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases), Base Editing, and Prime Editing are commonly used technologies utilized in the development & optimization of recombinant proteins. Of these, CRISPR-Cas9 is an extensively employed technique utilized to edit the genomes of various organisms used in protein expression. This technology allows researchers to intricately modify the genomes of host cells designated for protein expression, facilitating a spectrum of optimizations. For instance, it has been observed that CRISPR-Cas9 technique coupled with HEK293 cells is used to establish a stable recombinant proteins production cell line, ultimately increasing the industrial potential of human-derived cell hosts as per the Carnegie Mellon University (Qatar).
Challenge: Challenges associated with delivery systems
Development of an efficient delivery system for recombinant proteins presents a challenge in biotechnology & medicine. Biological barriers, such as cellular membranes and mucosal or blood-brain barriers, pose obstacles to effective protein delivery. Key considerations include overcoming biological barriers, maintaining protein stability, achieving target specificity, reducing immunogenicity, and controlling dosage. Biological barriers, such as cellular membranes and mucosal or blood-brain barriers, pose obstacles to effective protein delivery.
Recombinant proteins Market Ecosystem
The Growth Factors & Chemokines segment is projected to hold the dominant position in the recombinant proteins industry during the forecast period.
On the basis of product, the recombinant proteins market is divided into various segments: Immune Response Proteins, Growth Factors & Chemokines, Structural Proteins, Membrane Proteins, Kinase Proteins, Regulatory Proteins, Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors and Other Recombinant proteins. The Dominant share can be accounted due to their application in cell signalling activities and in optimizing the production of high-quality recombinant proteins.
The drug discovery & development segment accounted for the largest share of the application segment in the recombinant proteins industry in 2023.
Based on application, the global recombinant proteins market is segmented into drug discovery & development, biopharmaceutical production, research, diagnostics and other applications. In 2022, the drug discovery & development segment accounted for the largest share of the market. The largest share can be attributed to the application of recombinant proteins in the drug discovery & development of novel compound that influence the function of disease-associated proteins or respective protein-protein interactions.
The bacterial cell segment accounted for the largest share of the recombinant proteins industry in 2022.
Based on host cell, the global recombinant proteins market is segmented into mammalian systems, insect cells, yeast & fungi, bacterial cells and other host cell. In 2022, the bacterial cell segment accounted for the largest share of the market. The largest share is accounted due to their well-defined genetic characteristics, cost-effectiveness compared to other systems and ease of manipulation.
Pharmaceutical & biopharmaceuticals companies segment accounted for the largest share of the recombinant proteins industry in 2022.
Based on end user, the global recombinant proteins market is segmented into, pharmaceutical & biopharmaceuticals companies, biotechnology companies, academic & research institutes, contract research organizations (CROs) and other end users. In 2022, pharmaceutical & biopharmaceuticals companies segment accounted for the largest share of the market. The key factor driving the growth of the this market segment includes, significant requirement of recombinant proteins in the identification of prognostic, predictive, and diagnostic markers and quantifying biomarkers in drug discovery & development.
North America was the largest regional market for recombinant proteins industry in 2022.
The recombinant proteins market is segmented into six major regions namely, North America, Europe, the Asia Pacific, Latin America, Middle East and Africa. In 2022, North America accounted for the largest share of the market, and this trend is expected to continue during the forecast period. Presence of prominent market players, a surge in chronic and infectious diseases, rising R&D expenditure, growing research initiatives in proteomics and genomics, and favorable government funding opportunities collectively are major factors contributing to the growth of market.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the recombinant proteins market include Bio-Techne (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Abnova Corporation (Taiwan), BioLegend Inc(US), Bio-Rad Laboratories, Inc. (US), BPS Bioscience, Inc. (US), Enzo Biochem Inc. (US), GenScript (China), Miltenyi Biotec B.V. & Co. KG (Germany), Proteintech Group, Inc.(US), Sino Biological Inc. (China), ACROBiosystems Group(US), Aviva Systems Biology Corporation (US), Sartorius CellGenix GmbH (Germany), Icosagen (US), Neuromics (US), ProSpec-Tany TechnoGene Ltd. (Israel), ProteoGenix S.A.S (France), RayBiotech Inc. (US), Laurus Bio (India), Stemcell Technologies Inc. (Canada), StressMarq Biosciences Inc. (Canada) and United States Biological (US).
Scope of the Recombinant Proteins Industry
|
Report Metric |
Details |
|
Market Revenue Size in 2023 |
$2.2 billion |
|
Projected Revenue Size by 2028 |
$3.2 billion |
|
Industry Growth Rate |
Poised to Grow at a CAGR of 7.2% |
|
Market Driver |
Rising incidence of chronic diseases |
|
Market Opportunity |
Advancements in gene editing technologies |
This report categorizes the recombinant proteins market to forecast revenue and analyze trends in each of the following submarkets:
By Product
-
Growth Factors and Chemokines
- Interferons (IFNs)
- Interleukins (ILs)
- Other growth factors & chemokines
- Immune Response Proteins
- Structural Proteins
- Membrane Proteins
- Kinase Proteins
- Regulatory Proteins
- Recombinant Metabolic Enzymes
- Adhesion Molecules and Receptors
- Other Recombinant Proteins
By Application
-
Drug Discovery & Development
- Biologics
- Vaccines
- Cell & Gene Therapy
- Biopharmaceutical Production
-
Research
- Academic Research
- Biotechnology Research
- Diagnostics
- Other Applications
By Host cell
- Mammalian Systems
- Insect Cells
- Yeast & Fungi
- Bacterial Cells
- Other host cell
By End User
- Pharmaceutical & Biopharmaceutical Companies
- Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (ROE)
-
Asia Pacific
- Japan
- China
- India
- South Korea
- Rest of Asia Pacific
-
Latin America
- Brazil
- RoLATAM
-
Middle East
- GCC Countries
- Rest of Middle East
- Africa
Recent Developments of Recombinant Proteins Industry:
- In February 2023, Bio-Techne (US) and Cell Signaling (US) entered into the partnership to allow researchers to validate simple western antibodies.
- In May 2023, Thermofisher Scientific Inc (US) and National Research and Innovation Agency of Indonesia (BRIN) signed a Memorandum of Understanding (MOU) for enabling and enhancing the national research and innovation infrastructure and capability in Indonesia
- In January 2022, Merck KGaA (Germany) and Ares Trading S.A (Switzerland) entered into a out-licensing agreement for sprifermin, recombinant form of human fibroblast growth factor 18.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global recombinant proteins market?
The global recombinant proteins market boasts a total revenue value of $3.2 billion by 2028.
What is the estimated growth rate (CAGR) of the global recombinant proteins market?
The global recombinant proteins market has an estimated compound annual growth rate (CAGR) of 7.2% and a revenue size in the region of $2.2 billion in 2023. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 33)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY (Page No. - 38)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 RECOMBINANT PROTEINS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY SIDE ANALYSIS (2022)
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, APPLICATION, HOST CELL, AND END USER)
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
FIGURE 8 RECOMBINANT PROTEINS INDUSTRY: CAGR PROJECTIONS (2023–2028)
FIGURE 9 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024−2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY (Page No. - 50)
FIGURE 11 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 12 RECOMBINANT PROTEINS INDUSTRY, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MARKET FOR RESEARCH, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 15 MARKET, BY HOST CELL, 2023 VS. 2028 (USD MILLION)
FIGURE 16 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF MARKET
4 PREMIUM INSIGHTS (Page No. - 56)
4.1 RECOMBINANT PROTEINS MARKET OVERVIEW
FIGURE 18 INCREASING GOVERNMENT SUPPORT FOR R&D IN LIFE SCIENCES TO DRIVE MARKET
4.2 NORTH AMERICA: RECOMBINANT PROTEINS INDUSTRY, BY PRODUCT (2022)
FIGURE 19 GROWTH FACTORS & CHEMOKINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 MARKET, BY PRODUCT, 2023 VS. 2028
FIGURE 20 GROWTH FACTORS & CHEMOKINES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 59)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 RECOMBINANT PROTEINS INDUSTRY: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of chronic diseases
FIGURE 23 NUMBER OF CANCER CASES IN US (2017 - 2022)
5.2.1.2 Increasing demand for biologics and biosimilars due to patent expiry
5.2.1.3 Increasing government support for R&D in life sciences
TABLE 5 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022)
5.2.1.4 Growing preference for personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 High production costs
5.2.2.2 Stringent regulatory approval processes
5.2.3 OPPORTUNITIES
5.2.3.1 Advancements in gene editing technologies
5.2.3.2 High growth potential of emerging markets
5.2.3.3 Emergence of novel expression systems
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with delivery systems
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 24 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR RECOMBINANT PROTEIN MANUFACTURERS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS
TABLE 6 RECOMBINANT PROTEIN PRODUCTS
5.4.2 AVERAGE SELLING PRICE TREND OF RECOMBINANT PROTEINS
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: MANUFACTURING & ASSEMBLY PHASE CONTRIBUTES MAXIMUM VALUE TO VALUE CHAIN OF RECOMBINANT PROTEINS
5.7 ECOSYSTEM MARKET/MAP
FIGURE 26 ECOSYSTEM MARKET/MAP
TABLE 7 MARKET: ROLE IN ECOSYSTEM:
5.8 REGULATORY ANALYSIS
TABLE 8 KEY REGULATORY AGENCIES
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 15 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 PATENT ANALYSIS
FIGURE 27 PATENT APPLICATIONS FOR RECOMBINANT PROTEINS, DECEMBER 2013–DECEMBER 2023
TABLE 16 MARKET: INDICATIVE LIST OF PATENTS
5.11 KEY CONFERENCES AND EVENTS
TABLE 17 DETAILED LIST OF KEY CONFERENCES AND EVENTS (2023–2024)
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RECOMBINANT PROTEINS
5.12.2 BUYING CRITERIA FOR RECOMBINANT PROTEINS
FIGURE 29 KEY BUYING CRITERIA FOR END USERS
6 RECOMBINANT PROTEINS MARKET, BY PRODUCT (Page No. - 92)
6.1 INTRODUCTION
TABLE 18 RECOMBINANT PROTEINS INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 GROWTH FACTORS & CHEMOKINES
TABLE 19 MARKET FOR GROWTH FACTORS & CHEMOKINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 21 NORTH AMERICA: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 EUROPE: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 LATIN AMERICA: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 MIDDLE EAST: MARKET FOR GROWTH FACTORS & CHEMOKINES, COUNTRY, 2021–2028 (USD MILLION)
6.2.1 INTERFERONS (IFNS)
6.2.1.1 Ability to regulate critical cellular processes across research applications to propel market
TABLE 26 MARKET FOR INTERFERONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 27 NORTH AMERICA: MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 28 EUROPE: MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 ASIA PACIFIC: MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 LATIN AMERICA: MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 MIDDLE EAST: MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2 INTERLEUKINS (ILS)
6.2.2.1 Rising focus on personalized therapeutics to drive market
TABLE 32 MARKET FOR INTERLEUKINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 33 NORTH AMERICA: MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 EUROPE: MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 ASAI PACIFIC: MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 LATIN AMERICA: MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 MIDDLE EAST: MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.3 OTHER GROWTH FACTORS & CHEMOKINES
TABLE 38 MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 39 NORTH AMERICA: MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 EUROPE: MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 ASIA PACIFIC: MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 LATIN AMERICA: MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 MIDDLE EAST: MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 IMMUNE RESPONSE PROTEINS
6.3.1 HIGH UTILIZATION OF IMMUNE CHECKPOINT PROTEINS IN CANCER IMMUNOTHERAPY TO PROPEL MARKET
TABLE 44 RECOMBINANT PROTEINS INDUSTRY FOR IMMUNE RESPONSE PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 EUROPE: MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 LATIN AMERICA: MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 MIDDLE EAST: MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 STRUCTURAL PROTEINS
6.4.1 ATTACHMENT FACTORS IN CELL CULTURE APPLICATIONS TO DRIVE MARKET
TABLE 50 MARKET FOR STRUCTURAL PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 LATIN AMERICA: MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 MIDDLE EAST: MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 MEMBRANE PROTEINS
6.5.1 ESSENTIAL PROCESS REGULATION OF STRUCTURAL CELLS TO SUPPORT MARKET GROWTH
TABLE 56 MARKET FOR MEMBRANE PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 EUROPE: MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 ASIA PACIFIC: MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 LATIN AMERICA: MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 MIDDLE EAST: MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.6 KINASE PROTEINS
6.6.1 ACTIVE METABOLIZATION OF LIPIDS AND NUCLEOTIDES TO DRIVE MARKET
TABLE 62 MARKET FOR KINASE PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 63 NORTH AMERICA: MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 EUROPE: MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 ASIA PACIFIC: MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 66 LATIN AMERICA: MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 MIDDLE EAST: MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.7 REGULATORY PROTEINS
6.7.1 ABILITY TO MODULATE CELLULAR PROCESSES TO DRIVE MARKET
TABLE 68 RECOMBINANT PROTEINS INDUSTRY FOR REGULATORY PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 MARKET FOR REGULATORY PROTEINS IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 EUROPE: MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 LATIN AMERICA: MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 MIDDLE EAST: MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.8 RECOMBINANT METABOLIC ENZYMES
6.8.1 HIGH ADOPTION IN BIOTECHNOLOGICAL APPLICATIONS FOR THERAPEUTIC DEVELOPMENT TO BOOST DEMAND
TABLE 74 MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY REGION, 2021–2028 (USD MILLION)
TABLE 75 NORTH AMERICA: MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 LATIN AMERICA: MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 MIDDLE EAST: MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
6.9 ADHESION MOLECULES & RECEPTORS
6.9.1 ENHANCED FACILITATION OF EXTRACELLULAR MATRIX INTERACTIONS TO SUPPORT MARKET GROWTH
TABLE 80 MARKET FOR ADHESION MOLECULES & RECEPTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 81 NORTH AMERICA: MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 EUROPE: MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 ASIA PACIFIC: MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 LATIN AMERICA: MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 MIDDLE EAST: MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
6.10 OTHER RECOMBINANT PROTEINS
TABLE 86 MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 87 NORTH AMERICA: MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 EUROPE: MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 ASIA PACIFIC: MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 LATIN AMERICA: MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 MIDDLE EAST: MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
7 RECOMBINANT PROTEINS MARKET, BY APPLICATION (Page No. - 136)
7.1 INTRODUCTION
TABLE 92 RECOMBINANT PROTEINS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
7.2 DRUG DISCOVERY & DEVELOPMENT
TABLE 93 MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 94 MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)
TABLE 95 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 LATIN AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 99 MIDDLE EAST: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1 BIOLOGICS
7.2.1.1 High adoption in autoimmune disease & cancer treatment to propel market
TABLE 100 MARKET: KEY BIOLOGICS AND INDICATIONS
TABLE 101 MARKET FOR BIOLOGICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 102 NORTH AMERICA: MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 EUROPE: MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 104 ASIA PACIFIC: MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 LATIN AMERICA: MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 MIDDLE EAST: MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.2 VACCINES
7.2.2.1 Rising incidence of infectious diseases to boost demand
TABLE 107 MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 108 NORTH AMERICA: MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 EUROPE: MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 110 ASIA PACIFIC: MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 111 LATIN AMERICA: MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 MIDDLE EAST: MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.3 CELL & GENE THERAPY
7.2.3.1 Growing focus on CAR-T therapies to propel market
TABLE 113 RECOMBINANT PROTEINS INDUSTRY FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 114 NORTH AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 EUROPE: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 ASIA PACIFIC: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 LATIN AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 118 MIDDLE EAST: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 RESEARCH
TABLE 119 MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 120 MARKET FOR RESEARCH, BY REGION, 2021–2028 USD MILLION)
TABLE 121 NORTH AMERICA: MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 122 EUROPE: MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 123 ASIA PACIFIC: MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 124 LATIN AMERICA: MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 125 MIDDLE EAST: MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
7.3.1 ACADEMIC RESEARCH
7.3.1.1 Wide application in molecular & gene expression studies to propel market
TABLE 126 MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 127 NORTH AMERICA: MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 128 EUROPE: MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 129 ASIA PACIFIC: MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 130 LATIN AMERICA: MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 131 MIDDLE EAST: MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
7.3.2 BIOTECHNOLOGY RESEARCH
7.3.2.1 Growing focus on bioengineering and genomics to fuel market
TABLE 132 MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2021–2028 (USD MILLION)
TABLE 133 NORTH AMERICA: MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 134 EUROPE: MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 136 LATIN AMERICA: MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 137 MIDDLE EAST: MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 BIOPHARMACEUTICAL PRODUCTION
7.4.1 INCREASING DEVELOPMENT OF PROTEIN-BASED DRUGS TO SUPPORT MARKET GROWTH
TABLE 138 RECOMBINANT PROTEINS INDUSTRY FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2021–2028 (USD MILLION)
TABLE 139 NORTH AMERICA: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 EUROPE: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 141 ASIA PACIFIC: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 142 LATIN AMERICA: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 143 MIDDLE EAST: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 DIAGNOSTICS
7.5.1 GROWING FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
TABLE 144 MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 145 NORTH AMERICA: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 146 EUROPE: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 147 ASIA PACIFIC: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 148 LATIN AMERICA: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 149 MIDDLE EAST: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 OTHER APPLICATIONS
TABLE 150 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 151 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 152 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 153 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 154 LATIN AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 155 MIDDLE EAST: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8 RECOMBINANT PROTEINS MARKET, BY HOST CELL (Page No. - 171)
8.1 INTRODUCTION
TABLE 156 RECOMBINANT PROTEINS INDUSTRY, BY HOST CELL, 2021–2028 (USD MILLION)
8.2 MAMMALIAN SYSTEMS
8.2.1 HIGH UPTAKE IN BIOTECHNOLOGY APPLICATIONS TO PROPEL MARKET
TABLE 157 MARKET FOR MAMMALIAN SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
TABLE 158 NORTH AMERICA: MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 159 EUROPE: MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 160 ASIA PACIFIC: MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 161 LATIN AMERICA: MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 162 MIDDLE EAST: MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 INSECT CELLS
8.3.1 COST-EFFICIENT AND HIGH-YIELD CHARACTERISTICS TO DRIVE MARKET
TABLE 163 MARKET FOR INSECT CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 164 NORTH AMERICA: MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 165 EUROPE: MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 166 ASIA PACIFIC: MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 167 LATIN AMERICA: MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 168 MIDDLE EAST: MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 YEAST & FUNGI
8.4.1 NEW APPLICATIONS IN VACCINE DEVELOPMENT AND DIABETES TREATMENT TO BOOST DEMAND
TABLE 169 MARKET FOR YEAST & FUNGI, BY REGION, 2021–2028 (USD MILLION)
TABLE 170 MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 171 MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 172 MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 173 LATIN AMERICA: MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 174 MIDDLE EAST: MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 BACTERIAL CELLS
8.5.1 SIMPLIFIED GENETIC MANIPULATION AND SCALABILITY ADVANTAGES TO DRIVE MARKET
TABLE 175 RECOMBINANT PROTEINS INDUSTRY FOR BACTERIAL CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 176 MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 177 MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 178 ASIA PACIFIC: MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 179 LATIN AMERICA: MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 180 MIDDLE EAST: MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
8.6 OTHER HOST CELLS
TABLE 181 MARKET FOR OTHER HOST CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 182 NORTH AMERICA: MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 183 EUROPE: MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 184 ASIA PACIFIC: MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 185 LATIN AMERICA: MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 186 MIDDLE EAST: MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
9 RECOMBINANT PROTEINS MARKET, BY END USER (Page No. - 190)
9.1 INTRODUCTION
TABLE 187 RECOMBINANT PROTEINS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 RISING DEVELOPMENT OF GENE THERAPIES AND VACCINES TO PROPEL MARKET
TABLE 188 MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 189 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 190 EUROPE: MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 191 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 192 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 193 MIDDLE EAST: MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 BIOTECHNOLOGY COMPANIES
9.3.1 RISING NUMBER OF PROTEIN-BASED RESEARCH PROJECTS TO BOOST DEMAND
TABLE 194 MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 195 NORTH AMERICA: MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 196 EUROPE: MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 197 ASIA PACIFIC: MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 198 LATIN AMERICA: MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 199 MIDDLE EAST: MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 FAVORABLE GOVERNMENT INVESTMENTS TO PROPEL MARKET
TABLE 200 MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
TABLE 201 NORTH AMERICA: MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 202 EUROPE: MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 203 ASIA PACIFIC: MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 204 LATIN AMERICA: MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 205 MIDDLE EAST: MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 RISING OUTSOURCING OF CLINICAL TRIAL SERVICES TO SUPPORT MARKET GROWTH
TABLE 206 MARKET FOR CROS, BY REGION, 2021–2028 (USD MILLION)
TABLE 207 NORTH AMERICA: MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 208 EUROPE: MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 209 ASIA PACIFIC: MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 210 LATIN AMERICA: MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 211 MIDDLE EAST: MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
9.6 OTHER END USERS
TABLE 212 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 213 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 214 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 215 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 216 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 USD MILLION)
TABLE 217 MIDDLE EAST: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
10 RECOMBINANT PROTEINS MARKET, BY REGION (Page No. - 209)
10.1 INTRODUCTION
TABLE 218 RECOMBINANT PROTEINS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: RECOMBINANT PROTEINS MARKET SNAPSHOT
TABLE 219 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 220 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 221 NORTH AMERICA: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 222 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 223 NORTH AMERICA: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 224 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 225 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 USD MILLION)
TABLE 226 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 Rising investments in life sciences research to drive market
TABLE 227 US: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 228 US: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 229 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 230 US: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 231 US: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 232 US: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 233 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 High incidence of cancer and favorable healthcare investments to drive market
TABLE 234 CANADA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 235 CANADA: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 236 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 237 CANADA: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 238 CANADA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 239 CANADA: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 240 CANADA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
TABLE 241 EUROPE: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 242 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 243 EUROPE: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 244 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 245 EUROPE: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 246 EUROPE: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 247 EUROPE: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 248 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Growing focus on biotech clusters to drive market
TABLE 249 GERMANY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 250 GERMANY: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 251 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 252 GERMANY: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 253 GERMANY: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 254 GERMANY: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 255 GERMANY: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Rising demand for biologics and biosimilars to propel market
TABLE 256 UK: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 257 UK: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 258 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 259 UK: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 260 UK: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 261 UK: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 262 UK: RECOMBINANT PROTEINS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising establishment of biopharmaceutical production facilities to boost demand
TABLE 263 FRANCE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 264 FRANCE: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 265 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 266 FRANCE: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 267 FRANCE: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 268 FRANCE: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 269 FRANCE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Growth in proteomics and genomics research to drive market
TABLE 270 ITALY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 271 ITALY: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 272 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 273 ITALY: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 274 ITALY: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 275 ITALY: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 276 ITALY: RECOMBINANT PROTEINS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Rising establishment of pharmaceutical production facilities to drive market
TABLE 277 SPAIN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 278 SPAIN: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 279 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 280 SPAIN: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 281 SPAIN: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 282 SPAIN: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 283 SPAIN: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 284 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 285 REST OF EUROPE: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 286 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 287 REST OF EUROPE: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 288 REST OF EUROPE: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 289 REST OF EUROPE: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 290 REST OF EUROPE: RECOMBINANT PROTEINS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET SNAPSHOT
TABLE 291 ASIA PACIFIC: MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 292 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 293 ASIA PACIFIC: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 294 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 295 ASIA PACIFIC: MARKET FOR RESEARCH APPLICATION, BY TYPE, 2021–2028 (USD MILLION)
TABLE 296 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2021–2028 (USD MILLION)
TABLE 297 ASIA PACIFIC: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 298 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Expansion of R&D infrastructure to support market growth
TABLE 299 CHINA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 300 CHINA: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 301 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 302 CHINA: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 303 CHINA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 304 CHINA: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 305 CHINA: RECOMBINANT PROTEINS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Growth in pharmaceutical industry to propel market
TABLE 306 JAPAN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 307 JAPAN: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 308 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 309 JAPAN: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 310 JAPAN: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 311 JAPAN: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 312 JAPAN: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Rising demand for drug discovery & development to propel market
TABLE 313 INDIA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 314 INDIA: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 315 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 316 INDIA: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 317 INDIA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 318 INDIA: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 319 INDIA: RECOMBINANT PROTEINS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Rising incidence of infectious diseases to drive market
TABLE 320 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 321 SOUTH KOREA: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 322 SOUTH KOREA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 323 SOUTH KOREA: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 324 SOUTH KOREA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 325 SOUTH KOREA: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 326 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 327 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 328 REST OF ASIA PACIFIC: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 329 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 330 REST OF ASIA PACIFIC: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 331 REST OF ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 332 REST OF ASIA PACIFIC: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 333 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
TABLE 334 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 335 LATIN AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 336 LATIN AMERICA: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 337 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 338 LATIN AMERICA: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 339 LATIN AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 340 LATIN AMERICA: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 341 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 Rising incidence of chronic diseases to drive market
TABLE 342 BRAZIL: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 343 BRAZIL: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 344 BRAZIL: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 345 BRAZIL: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 346 BRAZIL: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 347 BRAZIL: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 348 BRAZIL: RECOMBINANT PROTEINS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 349 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 350 REST OF LATIN AMERICA: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 351 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 352 REST OF LATIN AMERICA: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 353 REST OF LATIN AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 354 REST OF LATIN AMERICA: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 355 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6 MIDDLE EAST
TABLE 356 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 357 MIDDLE EAST: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 358 MIDDLE EAST: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 359 MIDDLE EAST: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 360 MIDDLE EAST: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 361 MIDDLE EAST: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 362 MIDDLE EAST: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 363 MIDDLE EAST: RECOMBINANT PROTEINS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.6.1 MIDDLE EAST: RECESSION IMPACT
10.6.2 GCC COUNTRIES
10.6.2.1 Rising government investments in healthcare to support market growth
TABLE 364 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 365 GCC COUNTRIES: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 366 GCC COUNTRIES: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 367 GCC COUNTRIES: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 368 GCC COUNTRIES: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 369 GCC COUNTRIES: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 370 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6.3 REST OF THE MIDDLE EAST
TABLE 371 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 372 REST OF THE MIDDLE EAST: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 373 REST OF THE MIDDLE EAST: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 374 REST OF THE MIDDLE EAST: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 375 REST OF THE MIDDLE EAST: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 376 REST OF THE MIDDLE EAST: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 377 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.7 AFRICA
10.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
TABLE 378 AFRICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 379 AFRICA: MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 380 AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 381 AFRICA: MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 382 AFRICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 383 AFRICA: MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 384 AFRICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE (Page No. - 310)
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES
FIGURE 32 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
11.3 REVENUE SHARE ANALYSIS
FIGURE 33 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020−2022)
11.4 MARKET SHARE ANALYSIS
FIGURE 34 RECOMBINANT PROTEINS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 385 RECOMBINANT PROTEINS INDUSTRY: INTENSITY OF COMPETITIVE RIVALRY
11.5 COMPANY EVALUATION MATRIX
FIGURE 35 RECOMBINANT PROTEINS INDUSTRY: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPETITIVE BENCHMARKING
11.5.5.1 Product footprint (15 companies)
TABLE 386 RECOMBINANT PROTEINS INDUSTRY: COMPANY PRODUCT FOOTPRINT
11.5.5.2 Regional footprint
TABLE 387 RECOMBINANT PROTEINS INDUSTRY: REGIONAL FOOTPRINT ANALYSIS
11.6 START-UP/SME EVALUATION MATRIX
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 36 RECOMBINANT PROTEINS INDUSTRY: COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022)
11.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES
TABLE 388 RECOMBINANT PROTEINS INDUSTRY: PRODUCT FOOTPRINT
TABLE 389 RECOMBINANT PROTEINS INDUSTRY: REGIONAL FOOTPRINT
11.7 COMPETITIVE SCENARIO
11.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 390 RECOMBINANT PROTEINS INDUSTRY: PRODUCT LAUNCHES & APPROVALS, (JANUARY 2021–SEPTEMBER 2023)
11.7.2 DEALS
TABLE 391 RECOMBINANT PROTEINS INDUSTRY: DEALS (JANUARY 2021−SEPTEMBER 2023)
11.7.3 OTHER DEVELOPMENTS
TABLE 392 RECOMBINANT PROTEINS MARKET: OTHER DEVELOPMENTS (JANUARY 2021−SEPTEMBER 2023)
12 COMPANY PROFILES (Page No. - 324)
(Business overview, Products offered, Recent developments & MnM View)*
12.1 KEY PLAYERS
12.1.1 BIO-TECHNE
TABLE 393 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 37 BIO-TECHNE: COMPANY SNAPSHOT (2022)
TABLE 394 BIO-TECHNE: PRODUCTS OFFERED
TABLE 395 BIO-TECHNE: DEALS
TABLE 396 BIO-TECHNE: OTHER DEVELOPMENTS
12.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 397 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
TABLE 398 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 399 THERMO FISHER SCIENTIFIC INC: DEALS
12.1.3 MERCK KGAA
TABLE 400 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2022)
TABLE 401 MERCK KGAA: PRODUCTS OFFERED
TABLE 402 MERCK KGAA: DEALS
TABLE 403 MERCK KGAA: OTHER DEVELOPMENTS
12.1.4 ABCAM PLC
TABLE 404 ABCAM PLC: BUSINESS OVERVIEW
FIGURE 40 ABCAM PLC: COMPANY SNAPSHOT (2022)
TABLE 405 ABCAM PLC: PRODUCTS OFFERED
TABLE 406 ABCAM PLC: DEALS
TABLE 407 ABCAM PLC: OTHER DEVELOPMENTS
12.1.5 ABNOVA CORPORATION
TABLE 408 ABNOVA CORPORATION: BUSINESS OVERVIEW
TABLE 409 ABNOVA CORPORATION: PRODUCTS OFFERED
12.1.6 BIOLEGEND, INC
TABLE 410 BIOLEGEND INC: BUSINESS OVERVIEW
TABLE 411 BIOLEGEND INC: PRODUCTS OFFERED
12.1.7 BIO-RAD LABORATORIES, INC.
TABLE 412 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 41 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
TABLE 413 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
12.1.8 BPS BIOSCIENCE, INC.
TABLE 414 BPS BIOSCIENCE, INC.: BUSINESS OVERVIEW
TABLE 415 BPS BIOSCIENCE, INC.: PRODUCTS OFFERED
12.1.9 ENZO LIFE SCIENCES, INC. (SUBSIDIARY OF ENZO BIOCHEM, INC.)
TABLE 416 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
FIGURE 42 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022)
TABLE 417 ENZO BIOCHEM, INC.: PRODUCTS OFFERED
TABLE 418 ENZO BIOCHEM, INC.: OTHER DEVELOPMENTS
12.1.10 GENSCRIPT
TABLE 419 GENSCRIPT: BUSINESS OVERVIEW
FIGURE 43 GENSCRIPT: COMPANY SNAPSHOT (2022)
TABLE 420 GENSCRIPT: PRODUCTS OFFERED
12.1.11 MILTENYI BIOTEC B.V. & CO. KG
TABLE 421 MILTENYI BIOTEC B.V. & CO. KG: BUSINESS OVERVIEW
TABLE 422 MILTENYI BIOTEC B.V. & CO. KG: PRODUCTS OFFERED
TABLE 423 MILTENYI BIOTEC B.V. & CO. KG: PRODUCT LAUNCHES
12.1.12 PROTEINTECH GROUP, INC.
TABLE 424 PROTEINTECH GROUP, INC.: BUSINESS OVERVIEW
TABLE 425 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED
TABLE 426 PROTEINTECH GROUP, INC.: DEALS
TABLE 427 PROTEINTECH GROUP, INC.: OTHER DEVELOPMENTS
12.1.13 SINO BIOLOGICAL, INC.
TABLE 428 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
TABLE 429 SINO BIOLOGICAL, INC.: PRODUCTS OFFERED
TABLE 430 SINO BIOLOGICAL, INC.: PRODUCT LAUNCHES
TABLE 431 SINO BIOLOGICAL, INC.: DEALS
TABLE 432 SINO BIOLOGICAL, INC.: OTHER DEVELOPMENTS
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 ACROBIOSYSTEMS GROUP
12.2.2 AVIVA SYSTEMS BIOLOGY CORPORATION
12.2.3 SARTORIUS CELLGENIX GMBH
12.2.4 ICOSAGEN
12.2.5 NEUROMICS
12.2.6 PROSPEC-TANY TECHNOGENE LTD.
12.2.7 PROTEOGENIX S.A.S
12.2.8 RAYBIOTECH, INC.
12.2.9 LAURUS BIO
12.2.10 STEMCELL TECHNOLOGIES
12.2.11 STRESSMARQ BIOSCIENCES INC.
12.2.12 UNITED STATES BIOLOGICAL
13 APPENDIX (Page No. - 399)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the recombinant proteins market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the recombinant proteins market. The secondary sources used for this study include The Antibody Society, Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), American Medical Association (AMA), Recombinant Antibody Network (RAN) National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Department of Agriculture (USDA), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), Institute for Molecular Medicine, Annual Reports, SEC Filings, Press Releases, Company Websites, Investor Presentations, Magazines, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global recombinant proteins market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the recombinant proteins market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The major players in the industry and market have been identified through extensive primary and secondary research.
- The revenues generated from the recombinant proteins service business of players operating in the market have been determined through secondary research and primary analysis.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Global Recombinant proteins Market Size :Bottom-Up Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Top-Down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
- Recombinant proteins are manipulated forms of proteins that are generated by recombinant DNA technology which modifies the gene sequences. These are formed by transfecting foreign genes into a host cell. They are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses.
Key Stakeholders
- Pharmaceutical and biotechnology companies
- Life sciences companies
- Academic research institutes
- Government institutes
- Private research firms
- Contract Research Organizations (CROs)
- Third-party suppliers, direct suppliers, distributors, and channel partners
- Venture capitalists and investors
- Market research and consulting firms
Report Objectives
- To define, describe, and forecast the recombinant proteins market by product, application, host cell, end user, and region.
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall recombinant proteins market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa.
- To profile the key players and analyze their market shares and core competencies2
- To track and analyze competitive developments, such as acquisitions, product launches, expansions, agreements, partnerships and research & development activities.
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the recombinant proteins Market
Generating Response ...
Growth opportunities and latent adjacency in Recombinant Proteins Market
What are the growth estimates for Recombinant protein market till 2026?
What are the key factors hampering growth of the Recombinant protein market?
Interested in data of Recombinant Protein Market, Industry Share, Size, Growth and forecasts of 2027 - 2030
How big is the recombinant proteins market?